GO FUND IT NOW

INSTITUTE FOR MOLECULAR MEDICINE

Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.

Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. is a funding opportunity from INSTITUTE FOR MOLECULAR MEDICINE, up to 2115510, closing January 31, 2027.

Funder
INSTITUTE FOR MOLECULAR MEDICINE
Funding
2115510
Deadline
Jan 31, 2027
(185d left)

Overview

Project Summary Recent data from clinical trials with humanized or fully human mAbs targeting Aβ suggest that immunotherapy could clear/reduce brain amyloid plaques and even slow cognitive decline in vaccinated subjects when initiated as a preventive measure. However, passive immunotherapy with even the most…

See if your org is a fit, start free Official solicitation
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | Go Fund It Now